As the respiratory syncytial virus (RSV) vaccine field grapples with a significantly reduced market size thanks to regulatory ...
By Blake Brittain (Reuters) -British pharmaceutical giant GlaxoSmithKline and rival Pfizer have agreed to end a lawsuit that ...
GSK Plc and Pfizer Inc. settled a patent-infringement lawsuit over competing vaccines for RSV, ending the dispute in Delaware ...
GSK and Pfizer have settled a lawsuit alleging Pfizer’s RSV shot Abrysvo infringed GSK’s patents. A Pfizer ...
The European Commission approved Pfizer's respiratory syncytial virus vaccine for the prevention of lower respiratory tract ...
Just hours after thousands of U.S. Food and Drug Administration employees were shown the door, Barclay Butler, the agency’s ...
GlaxoSmithKline (NYSE:GSK) and Pfizer (NYSE:PFE) have agreed to dismiss a U.S. patent lawsuit over Pfizers RSV vaccine, ...
Pfizer (NYSE:PFE) recently saw the European Commission expand the authorization for its RSV vaccine, ABRYSVO, to include ...
Lastly, Pfizer is a solid dividend stock. It now offers a beefy 6.8% yield, and has increased its payouts by 53.6% in the ...
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has issued a decision amending the marketing ...
Pfizer (PFE) announced that the European Commission has issued a decision amending the marketing authorization for Abrysvo, the company’s ...
Pfizer (NYSE:PFE) and GSK (NYSE:GSK) on Thursday agreed to end a patent lawsuit over claims that the former’s vaccine, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback